34 results about "FGF1" patented technology

There is provided an FGF2 substitute containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation.

The invention relates to a preparation method of FGF1 sericin protein gel with activity for promoting cell proliferation and a product thereof. The preparation method comprises the following steps that sericin protein containing human FGF1 protein is extracted by human FGF1 gene modifying silk, and a sericin protein solution containing human FGF1 protein is obtained; after renaturation, an FGF1 sericin protein aqueous solution is obtained after dialysis with water, and FGF1 sericin protein hydrogel is obtained by centrifugation; and the FGF1 sericin protein hydrogel is placed at 4 DEG C, an FGF1 sericin protein gel material is formed by cross-linking of a chemical cross-linking agent or inducement of an inducer. The prepared gel material has the activity of promoting cell proliferation andhas broad application potential in tissue engineering.

The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

The invention relates to a skin anti-ageing composition, in particular to a skin care product containing kinds of biological factors, and belongs to the fields of cosmetics and biotechnologies. Every10 ml of composition is composed of, by content, 5-40 mg of transparent hyaluronic acid, 50-400 mg of hydrolyzed collagen, 1-5 ml of mesenchymal stem cell secretion, 1-5 ng of EGF, 1-8 ng of b-FGF1 and 10 ml of sufficiently-supplemented purified water. The skin anti-ageing composition has the advantages that a formula is safe and effective, there are no allergic substances and preservative, ageingresistance and wrinkle removal are effective, the premature ageing of the skin is improved greatly, meanwhile, it is avoided that nutrition excess makes the skin burdened, and new skin problems appear, and the skin anti-ageing composition is particularly suitable for allergic skin.

The invention relates to a preparation method and a product of a sericin-agarose composite gel having the activity of promoting cell proliferation and a product, sericin of recombinant FGF1 protein and FGF2 protein can be extracted from transgenic human FGF1 gene and human FGF2 gene silk, a sericin solution containing the recombinant FGF1 protein and the FGF2 protein is obtained, the sericin solution containing the recombinant FGF1 protein and the FGF2 protein is renatured to obtain a renatured sericin solution containing the recombinant FGF1 protein and the FGF2 protein, the renatured sericinsolution and an agarose solution are mixed for injection molding and molding to obtain the sericin-agarose composite gel having the activity of promoting cell proliferation, and the prepared composite gel has good stability, can better support the proliferation and growth of NIH3T3 cells, and has low cytotoxicity, and has broad application prospects in tissue engineering.

The invention relates to recombinant human acidic fibroblast growth factor (FGF1), in particular relates to a preparation method of FGF1 full-length protein by utilizing escherichia coli, which comprises the following steps of amplifying by utilizing a PCR (polymerase chain reaction) method to obtain a human FGF1 full-length gene PCR product; and digesting the PCR product by using incision enzyme. According to the preparation method, the full-length gene of the human acidic fibroblast growth factor is cloned to a pMAL-p5X expression carrier; the recombinant plasmid expresses the FGF1 full-length protein containing MBP (myelin basic protein) fusion label at high efficiency in the escherichia coli, wherein the protein in soluble expression; and the protein with MBP infusion label is purified by utilizing an MBP affinity column, and a complete FGF1 protein without the fusion label is prepared by utilizing TEV (tobacco etch virus) enzyme binding site and using TEV digested and purified infusion protein. The FGF1 full-length protein has high solubility and higher purity.

The invention provides a FGF1-FGF21 chimeric protein. The FGF1-FGF21 chimeric protein comprises a FGF1 mutant and a C-tail of FGF21. The FGF1-FGF21 chimeric protein reduces the side effects of mitogenesis and proliferation, and has long-acting blood-sugar-reducing and lipid-lowering activities and other activities.

The invention relates to the technical field of blood vessel production inhibition and discloses application of MiR-205-5p in preparation of a vascularization agent. The application comprises the following operations: detecting expression of miR-205-5p and CD31 in human gastric carcinoma tissue and liver metastatic tumor by adopting quantitative real-time qRT-PCR; detecting formation of capillaryvessels of endothelial cells of human umbilical veins in vitro, and researching actions of silence and high expression of the miR-205-5p in a body dorsa body wrinkle chamber model; and detecting influence on expression of VEGFA and FGF1 caused by the miR-205-5p by adopting the qRT-PCR and Western blots, wherein the MiR-205-5p lowers the expression of the VEGFA and FGF1 through an ERK signal way and direct targeting. According to the application, the expression of the VEGFA and FGF1 is lowered through the ERK signal way and direct targeting, so that vasculogenesis of gastric carcinoma is inhibited; particularly, the MiR-205-5p exerts an important action in the vasculogenesis; and the miR-205-5p can be used for lowering the formation of newborn blood vessels through negatively regulating andcontrolling the expression of the VEGFA, so that the miR-205-5p is a carcinoma inhibiting factor through inhibiting the vasculogenesis in the gastric carcinoma, and also exerts an important action onproliferation and invasion of different types of tumors.

The invention provides a novel fucosylated chondroitin sulfate FCS hm and a preparation method and an application thereof. The fucosylated chondroitin sulfate has the molecular weight of 50-200 kDa and has the sulfate content of 20-40%; a main chain of the fucosylated chondroitin sulfate is mainly composed of chondroitin sulfate A and chondroitin sulfate E. The FCS hm is mainly composed of four structural fragments, and a side chain contains 1-5 fucoses. The FCS hm exhibits good anticoagulant and antithrombotic activities through an endogenous coagulation pathway, is similar to low-molecular-weight heparin, and has inhibitory effects on FIIa and FXa mediated by antithrombin III. In addition, the FCS hm has high affinity with fibroblast growth factors FGF1 and FGF2, and has anti-angiogenesis effect. The preparation process of the compound provided by the invention has the advantages of low cost, simple operation and easy industrialized production.

The invention provides a breast cancer diagnosis kit based on combined detection of fibroblast growth factors FGF1 and FGF10 and interleukin IL6, and belongs to the field of protein detection. The breast cancer diagnosis kit comprises reagents for quantitatively detecting the FGF1, the FGF10 and the interleukin IL6. The invention also provides a preparation method of the kit. The kit for clinically diagnosing breast cancer has the advantages of convenience in operation, low cost, good specificity and good accuracy.

The invention provides an FGF1 (Fibroblast Growth Factor 1) mutant. The amino acid sequence of the mutant has mutation of Lys127, Lys128 and/or Lys133 on the basis of SEQ ID NO:1, and the mutant has a function of reducing cell division promotion and proliferation of a FGF1, but still has the activity of reducing blood sugar and the like.

The invention aims to provide a preparation method and application of a CHIR99021 and FGF1 nanoparticle combined myocardial tissue block. The preparation method of the CHIR99021 and FGF1 nanoparticlecombined myocardial tissue block comprises the following steps of: 1) preparing CHIR99021 and FGF1 nanoparticles; and 2) preparing a human induced pluripotent stem cell-derived myocardial tissue block(iCM-C + F-NP Patch) containing the CHIR99021 and FGF1 nanoparticles. The prepared human induced pluripotent stem cell-derived myocardial tissue block (iCM-C + F-NP Patch) containing the CHIR99021 and FGF1 nanoparticles is applied to treatment of animal ischemic heart disease. The CHIR99021 and FGF1 are combined for use, so that proliferation of hiPSC-CMs can be promoted and apoptosis can be reduced through synergistic effect; when the CHIR99021 and FGF1 are used for treating the animal ischemic heart disease, more hiPSC-CMs can be survived after transplantation, myocardial infarction can beeffectively relieved, periodical activity of myocardial infarction transplantation cells can be promoted, angiogenesis can be promoted, apoptosis reaction can be reduced, and the CHIR99021 and FGF1 nanoparticle combined myocardial tissue block can be applied to clinical treatment of the myocardial infarction.